|Bid||1.60 x 2600|
|Ask||1.62 x 500|
|Day's Range||1.57 - 1.70|
|52 Week Range||1.09 - 3.78|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 9, 2018 - May 14, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||5.17|
Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! Facebook, Inc. (NASDAQ: FB ) stock traded higher by ...
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on April 25) Eleven Biotherapeutics Inc (NASDAQ: EBIO ) Integra Lifesciences ...
Catabasis Pharmaceuticals, Inc. (CATB), a clinical-stage biopharmaceutical company, today reported new positive magnetic resonance efficacy results showing slowed disease progression in boys with Duchenne muscular dystrophy (DMD) in the MoveDMD trial through 48 weeks of edasalonexent treatment. Both magnetic resonance imaging (MRI) and magnetic resonance spectroscopy (MRS) were performed in the Phase 2 MoveDMD trial and open-label extension. Statistically significant improvement in the rate of change in lower leg composite MRI T2 at 12, 24, 36 and 48 weeks on oral 100 mg/kg of edasalonexent treatment were observed compared to the off-treatment control period (p
Catabasis Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company, today announced that it will present new magnetic resonance imaging data from the open-label extension MoveDMD trial of edasalonexent for the treatment of Duchenne muscular dystrophy at the American Academy of Neurology 70th Annual Meeting to be held April 21 – 27, 2018, in Los Angeles, CA, at the Los Angeles Convention Center....
Alnylam (ALNY) announced encouraging results from phase I and phase I/II open-label extension studies of givosiran, which is being evaluated for the treatment of acute hepatic porphyrias.
Shares of Alkermes (ALKS) rose when the FDA accepted for review the new drug application for its depression candidate ALKS 5461 two weeks after it had issued a Refusal to File letter.
Catabasis Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company, today announced a restructuring of the organization to focus resources on the Company’s late-stage lead program, edasalonexent for the treatment of Duchenne muscular dystrophy .
Geron (GERN) telomerase inhibitor, imetelstat, is being evaluated in two late stage studies. The candidate is progressing well in the Janssen sponsored studies.
Bellicum (BLCM) agrees to make amendments to the protocols relating to clinical studies evaluating its T Cell Therapy, BPX-501.
Epizyme (EPZM) publishes tazemetostat phase I clinical data in The Lancet Oncology. The study demonstrated favorable safety findings and anti-tumor activity.
Spectrum Pharmaceuticals' (SPPI) poziotinib shows encouraging results in preliminary analysis of data from phase II lung cancer study.
Stock Monitor: Catabasis Pharma Post Earnings Reporting LONDON, UK / ACCESSWIRE / March 23, 2018 / Active-Investors.com has just released a free research report on Eiger BioPharma, Inc. (NASDAQ: EIGR ) ...
The Cambridge, Massachusetts-based company said it had a loss of 24 cents per share. The biopharmaceutical company posted revenue of $250,000 in the period. For the year, the company reported that its ...
Catabasis Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company, today reported financial results for the fourth quarter and full year ended December 31, 2017, and reviewed recent business progress.
NEW YORK, NY / ACCESSWIRE / March 15, 2018 / Catabasis Pharmaceuticals Inc (NASDAQ: CATB ) will be discussing their earnings results in their Q4 Earnings Call to be held on March 15, 2018, at 4:30 PM Eastern ...
SOLNA, Sweden, March 11, 2018 /PRNewswire/ -- Catella AB has, through Catella Property Fund Management AB ("CPFM"), signed a share purchase agreement to acquire a majority stake in the leading UK real estate investment and asset management company, APAM Ltd. Closing of the transaction requires regulatory approval and other conditions to be fulfilled. APAM Ltd ("APAM") has experienced fast growth over recent years and had revenues of approximately GBP 7 million during the calendar year 2017.
Catabasis Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company, will report fourth quarter and full year 2017 financial results after the NASDAQ Global Market close on Thursday, March 15, 2018.
NEW YORK, March 07, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...
NEW YORK, NY / ACCESSWIRE / March 2, 2018 / Markets continued to slide Thursday after President Trump announced that tariffs on steel and aluminum imports were on the way. The Dow Jones Industrial Average ...
NEW YORK, NY / ACCESSWIRE / February 14, 2018 / Strong performances from banking and technology stocks helped lift the markets further into the green on Tuesday. The Dow Jones Industrial Average gained ...
Catabasis Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company, today reported new positive efficacy and safety results showing preservation of muscle function and sustained disease-modifying effects in boys with Duchene muscular dystrophy in the MoveDMD trial open-label extension following 48 and 60 weeks of treatment with edasalonexent.